CR20110302A - ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 - Google Patents

ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3

Info

Publication number
CR20110302A
CR20110302A CR20110302A CR20110302A CR20110302A CR 20110302 A CR20110302 A CR 20110302A CR 20110302 A CR20110302 A CR 20110302A CR 20110302 A CR20110302 A CR 20110302A CR 20110302 A CR20110302 A CR 20110302A
Authority
CR
Costa Rica
Prior art keywords
azepan
blockers
oxazolidinonas
espiro
potassium channel
Prior art date
Application number
CR20110302A
Other languages
English (en)
Inventor
Pieter Smid
Michael Mlinaric
Josephus H M Lange
Konrad F Koehler
Sara Nunez-Garcia
Elmar Wegener
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of CR20110302A publication Critical patent/CR20110302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a espiro azepan oxazolidinonas como bloqueadores del canal de calcio Kv1.3 voltaje dependiente, a composiciones farmacéuticas que contienen estos compuestos, a métodos para preparar los compuestos, a métodos para preparar nuevos compuestos intermedios útiles para su síntesis, y a métodos para preparar composiciones.
CR20110302A 2008-12-12 2011-06-03 ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 CR20110302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12191308P 2008-12-12 2008-12-12
EP08171421 2008-12-12

Publications (1)

Publication Number Publication Date
CR20110302A true CR20110302A (es) 2011-10-27

Family

ID=40513443

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110302A CR20110302A (es) 2008-12-12 2011-06-03 ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3

Country Status (20)

Country Link
US (1) US8575148B2 (es)
EP (1) EP2376501A1 (es)
JP (1) JP2012511546A (es)
KR (1) KR20110110165A (es)
CN (1) CN102333782A (es)
AR (1) AR074558A1 (es)
AU (1) AU2009324358A1 (es)
BR (1) BRPI0922714A2 (es)
CA (1) CA2743557A1 (es)
CO (1) CO6390036A2 (es)
CR (1) CR20110302A (es)
DO (1) DOP2011000164A (es)
EA (1) EA201170801A1 (es)
EC (1) ECSP11011118A (es)
IL (1) IL212948A0 (es)
MX (1) MX2011006221A (es)
PE (1) PE20110772A1 (es)
TW (1) TW201026708A (es)
WO (1) WO2010066840A1 (es)
ZA (1) ZA201104041B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014008065A2 (pt) * 2011-10-03 2019-09-24 Kineta One Llc tratamento de obesidade e distúrbios relacionados a obesidade por direcionamento farmacológico de canais de potássio kv1.3
WO2014067861A1 (en) * 2012-10-29 2014-05-08 F. Hoffmann-La Roche Ag 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
CN109053751A (zh) * 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂
US20220356176A1 (en) * 2019-06-12 2022-11-10 The Johns Hopkins University Kv11.1-3.1 INHIBITING METHODS AND COMPOSITIONS
KR20220079575A (ko) * 2019-10-07 2022-06-13 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물
CN111574537B (zh) * 2020-05-20 2022-11-15 成都药明康德新药开发有限公司 叔丁基-8-氧杂-3,11-二氮杂螺[5.6]十二烷-3-甲酸基酯的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors

Also Published As

Publication number Publication date
ECSP11011118A (es) 2011-07-29
BRPI0922714A2 (pt) 2016-01-05
EP2376501A1 (en) 2011-10-19
CN102333782A (zh) 2012-01-25
US20110237569A1 (en) 2011-09-29
JP2012511546A (ja) 2012-05-24
KR20110110165A (ko) 2011-10-06
CA2743557A1 (en) 2010-06-17
AR074558A1 (es) 2011-01-26
IL212948A0 (en) 2011-07-31
US8575148B2 (en) 2013-11-05
WO2010066840A1 (en) 2010-06-17
EA201170801A1 (ru) 2011-12-30
PE20110772A1 (es) 2011-10-19
CO6390036A2 (es) 2012-02-29
TW201026708A (en) 2010-07-16
ZA201104041B (en) 2012-11-28
AU2009324358A1 (en) 2011-06-23
MX2011006221A (es) 2011-06-28
DOP2011000164A (es) 2011-06-30

Similar Documents

Publication Publication Date Title
CR20110302A (es) ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
HN2008000178A (es) Compuestos triciclicos, composiciones y procedimientos
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
ECSP067025A (es) DERIVADOS DE TETRAAZABENZO [e] AZULENO Y SUS ANÁLOGOS
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
ECSP11011517A (es) Compuestos antivirales
CR11524A (es) Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
PA8842101A1 (es) Heteroarilos sustituidos
HN2006032615A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
CR20120204A (es) Nuevo uso antitumoral de cabazitaxel
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
CO6410291A2 (es) 3-amino-2-mercaptoquinolina sustituidacomo modulador de kcnq2/3
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
ECSP11010753A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CR11392A (es) Derivados de pirazol como inhibidores de 5-lo
ECSP10010578A (es) Composicion farmaceutica 271
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)